RICHMOND, BRITISH COLUMBIA--(Marketwire - September 09, 2009) - Wispering Oaks International, Inc. d/b/a BioCurex (OTCBB: BOCX) - today announced that it has appointed Dr. Denis Burger and Dr. Jim Walsh to its Board of Directors.
Dr. Burger will also assume the position of Executive Chairman of BioCurex. He is a Director of both Trinity Biotech plc, a successful diagnostics company, and Lorus Therapeutics, a cancer therapeutics company. Dr. Burger was the past Chairman, Chief Executive Officer and a director of AVI Biopharma Inc, a publicly held biotechnology company. Dr. Burger is also a partner in Sovereign Ventures, a healthcare consulting and funding firm based in Portland, Oregon. He co-founded and acted as Chairman of Epitope Inc. until 1990. In addition, Dr. Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health Sciences University in Portland. Dr. Burger received his MSc and PhD in Microbiology and Immunology from the University of Arizona.
Dr. Burger stated: “From my 30 years of experience in the field, I am acutely aware of the importance of the relationship between early cancer diagnosis and successful treatment. I look forward to the opportunity to assist BioCurex in connection with its development efforts in the field of cancer diagnostics.”
Dr. Jim Walsh is appointed as a non-executive Director. He has 20 years general management experience in the healthcare industry with particular experience in diagnostics. He is a Director of Trinity Biotech Plc, (NASDAQ: TRIB) and is also a Director of PuriCore Plc. (LSE: PURI), a US-based healthcare company. He is currently CEO of Biosensia Ltd., a point of care diagnostics company, and interim CEO of Stokes Bio Ltd., a company specializing in the area of molecular diagnostics. He is an investment advisor to Bank of Ireland Kernel Capital Partners. Previously Dr. Walsh was Managing Director of Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc. Before joining CDL he worked with Fleming GmbH as R&D Manager. Born in Ireland, Dr Walsh is a graduate of the National University of Ireland and holds a Doctorate in Inorganic Chemistry and Post Doctorate qualifications in Immunochemistry.
Dr. Ricardo Moro, chief executive officer of BioCurex, stated: “I am very proud of the interest BioCurex has attracted from two executives of this caliber. Dr. Burger and Dr. Walsh bring decades of broad experience in the biotech industry. I look forward to working with them.”
About BioCurex:
BioCurex is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF™, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements’’ within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company’s actual results could differ materially from expected results.
Contacts:
BioCurex
Ricardo Moro
(604) 207-9150
